Blood Platelets Market Analysis

Blood Platelets Platelet Market Analysis

Based on platelet type, the blood platelets market is segmented as whole blood derived platelets and apheresis derived platelets. The whole blood derived platelets segment accounted for a revenue share of around 47% in 2022 and is expected to continue the same trend in the coming years. This segment expansion is majorly owing to the increased demand for whole blood derived platelets in healthcare settings due to its crucial role for transplant, oncology, and pediatric patients among others. Whole blood derived platelets are cost-effective, simplest, most common & flexible type of blood donation. This platelet type is employed to treat patients that require all the components of blood, such as those that have sustained significant blood loss due to surgery or trauma.
 

Based on application, the blood platelets market is segmented as hemophilia, thrombocytopenia, perioperative indications, platelet function disorders, hemato-oncology, and others. Thrombocytopenia segment is set to reach USD 3.5 billion by 2032. This high segmental share is owing to rising demand and increasing awareness related to extensive advantages delivered by the blood platelets in the precise management of thrombocytopenia. Platelet transfusion is highly indicated to treat or prevent bleeding in patients with thrombocytopenia disorder.
 

In several hospitals, the majority of platelet transfusions are delivered to non-bleeding, thrombocytopenic patients to decrease the risk of haemorrhage. The increasing prevalence of thrombocytopenia is also contributing to the segment revenue. As per the Rare Disease Advisor Council data 2022, the estimated global prevalence of immune thrombocytopenia is over 200,000 people at any one time. This disease prevalence is set to propel the adoption of the blood platelets.  
 

Based on end-use, the blood platelets market is segmented as hospitals, ambulatory surgical centers, and others. Hospitals segment is projected to reach USD 6.3 billion by 2032. This is owing to the soaring use of blood transfusion procedures in hospital settings offering enhanced outcomes is estimated to surge the patient preference for hospitals. Growing admissions with target disorders comprising chronic & blood diseases and surging disease screening initiatives coupled with the accessibility of highly skilled healthcare professionals are some other attributes that are propelling the growth of the hospital segment positively.  
 

Additionally, the higher chronic disease incidence in developed countries with robust healthcare infrastructure is projected to positively impact segment development. Surging cancer cases, infections, and blood disorder prevalence will significantly propel the diagnosis & treatment rate at hospitals. Thus, accessibility to better treatment & diagnosis coupled with the rising prevalence of these ailments and associated conditions is estimated to boost patient visits to hospitals.
 

The U.S. dominated the North America blood platelets market is anticipated to exceed USD 1.8 billion by 2032. This significant market share is attributable to several factors such as the presence of major players, an increase in the demand for blood platelets, etc. The presence of prominent players such as America’s Blood Centers, the American National Red Cross, and Blood Centers of America among others are engaged in the novel technologies adoption that facilitates the industrial expansion in the region. The high prevalence of chronic & blood diseases and the rising hospital admission in the region emphasize the growing need for blood platelets in related procedures.